Collectionner le produit
Détails du produit
Synonyms
CD38, T10, cADPr hydrolase 1
Source
FITC-Labeled Human CD38, Fc Tag (CD8-HF255) is expressed from human 293 cells (HEK293). It contains AA Val 43 - Ile 300 (Accession # P28907-1). It is the FITC labeled form of Human CD38, Fc Tag (Cat. No. CD8-H5255).
Predicted N-terminus: Val 43
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a human IgG1 Fc tag at the C-terminus.
The protein has a calculated MW of 56.5 kDa. The protein migrates as 65-75 under reducing (R) condition (SDS-PAGE) due to glycosylation.
Conjugate
FITC
Excitation source: 488 nm spectral line, argon-ion laser
Excitation Wavelength: 488 nm
Emission Wavelength: 535 nm
Labeling
The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with FITC using standard chemical labeling method. The residual FITC is removed by molecular sieve treatment during purification process.
Protein Ratio
The FITC to protein molar ratio is 3-5.
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Shipping and Storage
This product is shipped at ambient temperature.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Les clients ont également consulté
Affichage des données
SDS-PAGE
FITC-Labeled Human CD38, Fc Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90%.
Bioactivity-ELISA
Immobilized Anti-CD38 Antibody (Daratumumab), Human IgG1 at 2 μg/mL (100 μL/well) can bind FITC-Labeled Human CD38, Fc Tag (Cat. No. CD8-HF255) with a linear range of 0.078-0.625 μg/mL (QC tested).
Protocol
Immobilized Monoclonal Anti-CD38 Antibody, Human IgG1 at 2 μg/mL (100 μL/well) can bind FITC-Labeled Human CD38, Fc Tag (Cat. No. CD8-HF255) with a linear range of 0.039-1.25 ug/mL (Routinely tested).
Protocol
Bioactivity-Flow Cytometry
2e5 of Anti-CD38 CAR-293 cells were stained with 100 μL of 3 μg/mL of FITC-Labeled Human CD38 Protein, Fc Tag (Cat. No. CD8-HF255) and negative control protein respectively. FITC signal was used to evaluate the binding activity (Routinely tested).
Protocol
Avis des utilisateurs Publier un commentaire
FAQ
- product
Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?
In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.
Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.
To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.
To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.
Supporting Document
Introduction de fond
Progrès de frontière
Progrès du développement médicamenteux- Nom anglais：
Lymphocyte differentiation antigen CD38
- Catégorie：
- Nombre de médicaments répertoriés：
3 Détails
- Nombre de médicaments cliniques：
47 Détails
- Étape de développement la plus élevée：
Approved
Contact Us
Drug Candidate Licensing
